An announcement from Precision BioSciences ( (DTIL) ) is now available.
Precision BioSciences, a leading gene editing company, has announced adjustments to its clinical leadership as it gears up for clinical trials in infectious diseases, such as hepatitis. Dr. Alan List, the current Chief Medical Officer, is set to retire but will stay on as a clinical consultant to provide strategic advice. He is succeeded by Dr. Murray Abramson as Senior Vice President of Clinical Development and John Fry as Strategic Clinical Advisor for hepatitis. This strategic reorganization aims to leverage their combined expertise in advancing Precision’s novel gene editing therapies, with a focus on initiating the development of their first in vivo gene editing candidate for hepatitis.
For a thorough assessment of DTIL stock, go to TipRanks’ Stock Analysis page.
